Assembly Biosciences, Inc. (ASMB) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Assembly Biosciences, Inc. (ASMB) trades at $26.47 with AI Score 35/100 (Grade D). Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for hepatitis B virus (HBV) infection. Market cap: $421M, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for ASMB: ASMB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ASMB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ASMB: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Assembly Biosciences, Inc. (ASMB) Healthcare & Pipeline Overview
Assembly Biosciences, Inc. is a clinical-stage biotechnology firm specializing in HBV therapeutics, with Vebicorvir advancing through clinical trials. The company differentiates itself through strategic collaborations and a pipeline targeting chronic HBV infection, operating within the competitive biotechnology landscape.
What Is the Investment Thesis for ASMB?
Assembly Biosciences presents a focused investment opportunity within the biotechnology sector, driven by its pipeline of HBV therapeutics. The company's lead candidate, Vebicorvir, having completed Phase 2 trials, represents a near-term value driver. Strategic collaborations with BeiGene, Arbutus, and Antios offer potential synergy and accelerated development of combination therapies. A key risk lies in the inherent uncertainty of clinical trials and regulatory approvals. The company's market capitalization of $421M reflects both the potential and the risks associated with its clinical-stage status. Successful advancement of its pipeline could significantly increase shareholder value, while clinical setbacks could negatively impact the stock. The company's negative profit margin of -9.0% underscores its reliance on future product revenue.
Based on FMP financials and quantitative analysis
ASMB Key Highlights
- Market capitalization of $421M reflects investor valuation of Assembly Biosciences' pipeline and potential.
- Gross margin of 77.2% indicates strong potential profitability upon commercialization of products.
- Beta of 1.16 suggests Assembly Biosciences' stock is slightly more volatile than the overall market.
- Vebicorvir's completion of Phase 2 clinical trials marks a significant milestone in the company's development pipeline.
- Strategic collaborations with BeiGene, Arbutus, and Antios provide opportunities for synergistic drug development and expanded market reach.
Who Are ASMB's Competitors?
ASMB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VIR Vir Biotechnology, Inc. | $9.42 | +2.06% | $1.59B | — |
| ABUS Arbutus Biopharma Corporation | $4.52 | +2.49% | $893M | 84 |
| GILD Gilead Sciences, Inc. | $129.78 | -2.57% | $161B | 94 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 70 |
| CRMD CorMedix Inc. | $8.19 | +5.27% | $643M | 95 |
| MDXG MiMedx Group, Inc. | $4.32 | -0.23% | $643M | 93 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ASMB's Key Strengths?
- Promising lead product candidate, Vebicorvir, in Phase 2 clinical trials.
- Strategic collaborations with BeiGene, Arbutus, and Antios.
- Strong intellectual property portfolio in the HBV therapeutic area.
- Experienced management team with expertise in drug development.
What Are ASMB's Weaknesses?
- Clinical-stage company with no currently marketed products.
- High research and development costs.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Negative profit margin and reliance on future product revenue.
What Could Drive ASMB Stock Higher?
- Announcement of Phase 3 clinical trial results for Vebicorvir.
- Initiation of clinical trials for ABI-H3733.
- Progression of ABI-4334 through preclinical development.
- Expansion of strategic collaborations and licensing agreements.
What Are the Key Risks for ASMB?
- Negative return on equity (-4.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for Vebicorvir and other drug candidates.
- Regulatory hurdles and competition from other HBV therapies.
- High research and development costs.
- Dependence on successful fundraising and investor support.
What Are the Growth Opportunities for ASMB?
- Advancement of Vebicorvir through Phase 3 clinical trials: Successful completion and positive results in Phase 3 trials for Vebicorvir could lead to regulatory approval and commercialization, capturing a significant share of the HBV therapeutics market. Timeline: Anticipated completion of Phase 3 trials within the next 2-3 years.
- Development of ABI-H3733: Continued development of ABI-H3733, currently in Phase 1a clinical study, represents a growth opportunity by expanding the company's pipeline with a novel therapeutic candidate. Positive results in early-stage trials could attract further investment and partnerships. The market for new HBV therapies is driven by the need for improved efficacy and safety profiles. Timeline: Progression through clinical trials over the next 3-5 years.
- Expansion of strategic collaborations: Forming new strategic collaborations with pharmaceutical companies and research institutions can provide access to new technologies, funding, and expertise. These collaborations can accelerate the development and commercialization of Assembly Biosciences' pipeline. The biotechnology industry is characterized by collaborative partnerships to share resources and mitigate risks. Timeline: Ongoing, with potential for new collaborations in the near term.
- Preclinical Development of ABI-4334: The continued preclinical development of ABI-4334 offers a future growth opportunity by expanding the company's HBV therapeutic options. Successful preclinical results could lead to clinical trials and potential market entry. The market for novel HBV treatments continues to grow, creating a need for innovative solutions. Timeline: Preclinical development ongoing, with potential clinical trials in 2-3 years.
- Triple Combination Therapy Evaluation: The collaboration with BeiGene, Arbutus Biopharma Corporation, and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection provides a growth opportunity through synergistic drug development. This approach could lead to more effective treatments and a larger market share. The combination therapy market is growing as it addresses complex diseases with multiple mechanisms. Timeline: Clinical trial results expected within the next 1-2 years.
What Opportunities Does ASMB Have?
- Advancement of Vebicorvir through Phase 3 clinical trials and potential commercialization.
- Expansion of pipeline with ABI-H3733 and ABI-4334.
- Formation of new strategic collaborations and licensing agreements.
- Growing market for HBV therapeutics with unmet medical needs.
What Threats Does ASMB Face?
- Clinical trial failures or delays.
- Regulatory hurdles and competition from other HBV therapies.
- Patent expiration and generic competition.
- Economic downturn and reduced healthcare spending.
What Are ASMB's Competitive Advantages?
- Proprietary drug candidates and intellectual property in the HBV therapeutic area.
- Clinical trial data demonstrating the safety and efficacy of its drug candidates.
- Strategic collaborations with leading pharmaceutical companies and research institutions.
- Expertise in HBV drug development and regulatory approval processes.
What Does ASMB Do?
Assembly Biosciences, Inc., founded in 2005 and headquartered in South San Francisco, California, is a clinical-stage biotechnology company dedicated to discovering and developing innovative therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Originally incorporated as Ventrus Biosciences, Inc., the company rebranded in June 2014 to reflect its focused approach on HBV therapeutics. The company's lead product candidate, Vebicorvir, has completed Phase 2 clinical trials, demonstrating the company's commitment to advancing potential treatments for patients with chronic HBV infection. In addition to Vebicorvir, Assembly Biosciences is also developing ABI-H3733, which has completed Phase 1a clinical study, and ABI-4334, currently in pre-clinical trials. These programs highlight the company's multi-faceted approach to addressing HBV infection. Assembly Biosciences strategically collaborates with other companies, including BeiGene, Ltd., Arbutus Biopharma Corporation, and Antios Therapeutics, Inc., to evaluate triple combination treatments for chronic HBV. The company also has strategic license agreements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC, further expanding its research and development capabilities. Assembly Biosciences operates primarily in the United States, focusing on addressing the unmet medical needs of individuals affected by HBV infection.
What Products and Services Does ASMB Offer?
- Discovers and develops therapeutic candidates for hepatitis B virus (HBV) infection.
- Focuses on developing treatments for patients with chronic HBV infection.
- Advances Vebicorvir through clinical trials.
- Develops ABI-H3733 and ABI-4334 as potential HBV therapies.
- Collaborates with other companies to evaluate combination treatments.
- Seeks strategic license agreements to expand research and development capabilities.
- Aims to address unmet medical needs in the HBV market.
How Does ASMB Make Money?
- Develops and patents novel therapeutic candidates for HBV infection.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
- Collaborates with other companies to share resources and accelerate drug development.
- Seeks regulatory approval from the FDA to commercialize its products.
- Generates revenue through product sales and licensing agreements.
What Industry Does ASMB Operate In?
Assembly Biosciences operates within the biotechnology industry, specifically targeting the hepatitis B virus (HBV) therapeutics market. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The HBV market is driven by the need for more effective and durable treatments for chronic HBV infection. Assembly Biosciences competes with larger pharmaceutical companies and other biotechnology firms developing HBV therapies. The company's success depends on its ability to develop and commercialize innovative therapies that address unmet medical needs in the HBV market.
Who Are ASMB's Key Customers?
- Patients with chronic hepatitis B virus (HBV) infection.
- Hospitals and clinics that treat HBV patients.
- Pharmaceutical companies that may license or acquire Assembly Biosciences' products.
- Healthcare providers who prescribe HBV therapies.
How Assembly Biosciences, Inc. Is Valued
Assembly Biosciences, Inc. carries a market capitalization of $421M, placing it in the small-cap category. Relative to its peer group, ASMB's quantitative score of 35/100 is below the peer average of 81/100.
Company Profile
Assembly Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Jason A. Okazaki. ASMB has traded publicly since 2010.
ROE -4%Key Financial Metrics
Return on equity for Assembly Biosciences, Inc. stands at -4.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Assembly Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.70 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Assembly Biosciences, Inc. revenue of about $45.5M for fiscal 2026, with EPS near $-1.70. The estimate reflects 3 contributing analysts.
ASMB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Promising lead product candidate, Vebicorvir, in Phase 2 clinical trials.
- Strategic collaborations with BeiGene, Arbutus, and Antios.
- Strong intellectual property portfolio in the HBV therapeutic area.
- Experienced management team with expertise in drug development.
Bear Case
- Clinical-stage company with no currently marketed products.
- High research and development costs.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Negative profit margin and reliance on future product revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ASMB Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
· Oct 9, 2019
ASMB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ASMB.
Price Targets
Wall Street price target analysis for ASMB.
ASMB MoonshotScore
What does this score mean?
The MoonshotScore rates ASMB 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jason A. Okazaki
Chief Executive Officer
Jason A. Okazaki serves as the Chief Executive Officer of Assembly Biosciences. His background includes extensive experience in the biotechnology and pharmaceutical industries. Prior to joining Assembly Biosciences, he held leadership positions at various companies, focusing on corporate strategy, business development, and commercial operations. His expertise spans across multiple therapeutic areas, including infectious diseases and liver diseases. He brings a wealth of knowledge in navigating the complexities of drug development and commercialization.
Track Record: Under Jason A. Okazaki's leadership, Assembly Biosciences has advanced its pipeline of HBV therapeutics, including the progression of Vebicorvir through Phase 2 clinical trials. He has overseen strategic collaborations with key partners, strengthening the company's research and development capabilities. His focus on innovation and strategic execution has positioned Assembly Biosciences as a leader in the HBV therapeutic space.
What Investors Ask About Assembly Biosciences, Inc. (ASMB) — Healthcare
What does the AI Score mean for ASMB?
ASMB holds an AI Score of 35/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for hepatitis B virus (HBV) infection. Their lead product candidate, Vebicorvir, has …
What does Assembly Biosciences, Inc. do?
Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative therapeutics for the treatment of hepatitis B virus (HBV) infection. The company's lead product candidate, Vebicorvir, has completed Phase 2 clinical trials and is being advanced towards Phase 3.
What do analysts say about ASMB stock?
Analyst coverage of Assembly Biosciences (ASMB) reflects a cautiously optimistic outlook, acknowledging the potential of its HBV pipeline while recognizing the inherent risks associated with clinical-stage biotechnology companies. Key valuation metrics often focus on the potential peak sales of Vebicorvir and other pipeline candidates, discounted by the probability of success and time to market.
What are the main risks for ASMB?
Assembly Biosciences faces several key risks inherent to its business model and the biotechnology industry. Clinical trial risk is paramount, as the failure or delay of Vebicorvir or other pipeline candidates could significantly impact the company's valuation. Regulatory risk is also significant, as the FDA approval process is complex and uncertain.
What are the key factors to evaluate for ASMB?
Assembly Biosciences, Inc. (ASMB) holds an AI score of 35/100 (low). Not financial advice.
How frequently does ASMB data refresh on this page?
ASMB's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ASMB's recent stock price performance?
Assembly Biosciences, Inc. (ASMB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising lead product candidate, Vebicorvir, in Phase 2 clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ASMB overvalued or undervalued right now?
Assembly Biosciences, Inc. (ASMB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ASMB before investing?
Before investing in Assembly Biosciences, Inc. (ASMB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- This is not investment advice. Conduct thorough research before making any investment decisions.